Original Article
Mitogen signal-associated pathways, energy metabolism regulation, and mediation of tumor immunogenicity play essential roles in the cellular response of malignant pleural mesotheliomas to platinum-based treatment: a retrospective study
Translational Lung Cancer Research
2021;
10
(7)
:3030-3042
.
(30 July 2021)
Diagnosis-to-surgery interval and survival for different histologies of stage I–IIA lung cancer
Translational Lung Cancer Research
2021;
10
(7)
:3043-3058
.
(30 July 2021)
Bevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open- label phase 2 study (CLEAR)
Translational Lung Cancer Research
2021;
10
(7)
:3059-3070
.
(30 July 2021)
Tumor PD-L1 expression is associated with outcomes in stage III non-small cell lung cancer (NSCLC) patients treated with consolidation durvalumab
Translational Lung Cancer Research
2021;
10
(7)
:3071-3078
.
(30 July 2021)
Randomized phase II trial of a first-in-human cancer cell lysate vaccine in patients with thoracic malignancies
Translational Lung Cancer Research
2021;
10
(7)
:3079-3092
.
(30 July 2021)
Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV
Translational Lung Cancer Research
2021;
10
(7)
:3093-3105
.
(30 July 2021)
Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?—a trial-level meta-analysis in PD-L1 selected subgroups
Translational Lung Cancer Research
2021;
10
(7)
:3106-3119
.
(30 July 2021)
Shared decision-making for prophylactic cranial irradiation in extensive-stage small-cell lung cancer: an exploratory study
Translational Lung Cancer Research
2021;
10
(7)
:3120-3131
.
(30 July 2021)
Subsequent systemic therapy for non-small cell lung cancer patients with immune checkpoint inhibitor-related interstitial lung disease
Translational Lung Cancer Research
2021;
10
(7)
:3132-3143
.
(30 July 2021)
Systemic immune-inflammation index is a stage-dependent prognostic factor in patients with operable non-small cell lung cancer
Translational Lung Cancer Research
2021;
10
(7)
:3144-3154
.
(30 July 2021)
Exosomal miR-375-3p breaks vascular barrier and promotes small cell lung cancer metastasis by targeting claudin-1
Translational Lung Cancer Research
2021;
10
(7)
:3155-3172
.
(30 July 2021)
Risk-score model to predict prognosis of malignant airway obstruction after interventional bronchoscopy
Translational Lung Cancer Research
2021;
10
(7)
:3173-3190
.
(30 July 2021)
Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapy
Translational Lung Cancer Research
2021;
10
(7)
:3191-3202
.
(30 July 2021)
A simplified model for determining the cutting plane during thoracoscopic anatomical partial lobectomy of the right lower lobe
Translational Lung Cancer Research
2021;
10
(7)
:3203-3212
.
(30 July 2021)
Detection of epidermal growth factor receptor (EGFR) mutations from preoperative circulating tumor DNA (ctDNA) as a prognostic predictor for stage I–III non-small cell lung cancer (NSCLC) patients with baseline tissue EGFR mutations
Translational Lung Cancer Research
2021;
10
(7)
:3213-3225
.
(30 July 2021)
Breast metastases from primary lung cancer: a retrospective case series on clinical, ultrasonographic, and immunohistochemical features
Translational Lung Cancer Research
2021;
10
(7)
:3226-3235
.
(30 July 2021)
Serum tumor markers for the prediction of concordance between genomic profiles from liquid and tissue biopsy in patients with advanced lung adenocarcinoma
Translational Lung Cancer Research
2021;
10
(7)
:3236-3250
.
(30 July 2021)
The prognostic role of the Transducin-like Enhancer of split protein family in lung adenocarcinoma
Translational Lung Cancer Research
2021;
10
(7)
:3251-3263
.
(30 July 2021)
Review Article
A narrative review of primary research endpoints of neoadjuvant therapy for lung cancer: past, present and future
Translational Lung Cancer Research
2021;
10
(7)
:3264-3275
.
(30 July 2021)
Hyperprogression under immunotherapy: a new form of immunotherapy response?—a narrative literature review
Translational Lung Cancer Research
2021;
10
(7)
:3276-3291
.
(30 July 2021)
Case Report
Adrenal crisis and acute exacerbation of interstitial lung disease after thymoma needle biopsy: a case report and literature review
Translational Lung Cancer Research
2021;
10
(7)
:3292-3302
.
(30 July 2021)
Acute anti-Ma2 paraneoplastic encephalitis associated to pembrolizumab: a case report and review of literature
Translational Lung Cancer Research
2021;
10
(7)
:3303-3311
.
(30 July 2021)
Mobile 3-dimensional (3D) C-arm system-assisted transbronchial biopsy and ablation for ground-glass opacity pulmonary nodules: a case report
Translational Lung Cancer Research
2021;
10
(7)
:3312-3319
.
(30 July 2021)
Editorial on Oligometastatic NSCLC: Definition and Treatment Opportunities1
Oligometastatic non-small cell lung cancer: from biology to clinical practice
Translational Lung Cancer Research
2021;
10
(7)
:3320-3323
.
(30 July 2021)
Local for advanced, is this a paradox?
Translational Lung Cancer Research
2021;
10
(7)
:3324-3328
.
(30 July 2021)
Review Article on Oligometastatic NSCLC: Definition and Treatment Opportunities1
Defining oligometastatic non-small cell lung cancer: concept versus biology, a literature review
Translational Lung Cancer Research
2021;
10
(7)
:3329-3338
.
(30 July 2021)
Epidemiology of oligometastatic non-small cell lung cancer: results from a systematic review and pooled analysis
Translational Lung Cancer Research
2021;
10
(7)
:3339-3350
.
(30 July 2021)
Narrative review: molecular and genetic profiling of oligometastatic non-small cell lung cancer
Translational Lung Cancer Research
2021;
10
(7)
:3351-3368
.
(30 July 2021)
A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done
Translational Lung Cancer Research
2021;
10
(7)
:3369-3384
.
(30 July 2021)
Diagnostic and prognostic biomarkers in oligometastatic non-small cell lung cancer: a literature review
Translational Lung Cancer Research
2021;
10
(7)
:3385-3400
.
(30 July 2021)
Clinical prognostic factors in surgically treated oligometastatic non-small cell lung cancer: a systematic review
Translational Lung Cancer Research
2021;
10
(7)
:3401-3408
.
(30 July 2021)
The role of the surgeon in the management of oligometastatic non-small cell lung cancer: a literature review
Translational Lung Cancer Research
2021;
10
(7)
:3409-3419
.
(30 July 2021)
Radiotherapy for oligometastatic non-small cell lung cancer: a narrative review
Translational Lung Cancer Research
2021;
10
(7)
:3420-3431
.
(30 July 2021)
Alternative methods for local ablation—interventional pulmonology: a narrative review
Translational Lung Cancer Research
2021;
10
(7)
:3432-3445
.
(30 July 2021)
Local ablative therapies in oligometastatic NSCLC-upfront or outback?—a narrative review
Translational Lung Cancer Research
2021;
10
(7)
:3446-3456
.
(30 July 2021)
Local ablative therapy in oncogenic-driven oligometastatic non-small cell lung cancer: present and ongoing strategies—a narrative review
Translational Lung Cancer Research
2021;
10
(7)
:3457-3472
.
(30 July 2021)
Current and future research efforts in oligometastatic non-small cell lung cancer—a systematic review
Translational Lung Cancer Research
2021;
10
(7)
:3473-3485
.
(30 July 2021)
How to optimize the incorporation of immunotherapy in trials for oligometastatic non-small cell lung cancer: a narrative review
Translational Lung Cancer Research
2021;
10
(7)
:3486-3502
.
(30 July 2021)
Disclosure:
1. The series “Oligometastatic NSCLC: definition and treatment opportunities” was commissioned by the Editorial office, Translational Lung Cancer Research without any sponsorship or funding. Maurizio V. Infante and Thierry Berghmans served as the unpaid Guest Editors for the series.
